OncoTherapy Science, Inc.

2026/11/20 20:23 Updated
Market Cap: $35.8M (¥5.7B)
Stock Price: $0.09 (¥14)
Exchange Rate: 1 USD = ¥159.74

Financial Summary for the Second Quarter of Fiscal Year Ending March 2027 (Interim) [Japanese GAAP] (Consolidated)

Revenue of 335 million yen, a decrease year-over-year. Interim operating loss was 568 million yen, ordinary loss was 572 million yen, and interim net loss attributable to owners of parent was 574 million yen. No earnings forecast for the fiscal year ending March 2027 is provided. Research and development investment continues, with increased costs in the cancer precision medicine-related business. Cash and deposits were 2,083 million yen, and equity experienced changes. New partnerships and clinical development continue.

Importance:
Page Updated: November 6, 2026
IR Disclosure Date: November 6, 2026

Key Figures

  • Revenue: 335 million yen (Year-over-Year -96 million yen)
  • Operating Loss: -568 million yen
  • Ordinary Loss: -572 million yen
  • Interim Net Loss Attributable to Owners of Parent: -574 million yen
  • Cash and Deposits: 2,083 million yen

AI要約

Overview of Business Results

Consolidated revenues for the interim period were 335 million yen, a decrease compared with the same period of the previous year. The primary causes were expense recognition for basic research and drug discovery research on pharmaceutical candidate compounds and increased cost of sales in the cancer precision medicine-related business, resulting in an operating loss of 568 million yen, an ordinary loss of 572 million yen, and an interim net loss attributable to owners of parent of 574 million yen. By segment, research and development related to pharmaceuticals recorded significant operating losses, and the cancer precision medicine-related business also posted losses. No earnings forecast for the fiscal year ending March 2027 is provided at this time.

Financial Position and Cash Flows

At the end of the interim period, total assets amounted to 2,338 million yen and net assets amounted to 2,062 million yen. Cash and deposits increased to 2,083 million yen. Shareholders' equity increased due to increases of 248 million yen in capital stock and 248 million yen in capital surplus, while retained earnings decreased by 574 million yen. Cash flows from operating activities continued to be negative, while cash flows from financing activities increased by 463 million yen due to funds raised through share issuance.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

OncoTherapy Science, Inc.

Company overview · Stock price · Financial data · All IR

View company page →